Edgar Filing: White Christopher G - Form 4

White Christ	opher G								
Form 4	-								
June 27, 201									
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								PPROVAL 3235-0287	
							Expires:January 3Expires:200Estimated averageburden hours perresponse0.		
(Print or Type F	Responses)								
1. Name and Address of Reporting Person <u>*</u> White Christopher G			2. Issuer Name and Ticker or Trading Symbol AMAG PHARMACEUTICALS INC. [AMAG]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O AMAG PHARMAC HAYDEN A	EUTICALS, IN	(Middle) C., 100	3. Date of	of Earliest Tr Day/Year)	ransaction		Director X Officer (give below) Chief Busi		
(Street) LEXINGTON, MA 02421			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
(City)	(State)	(Zip)	7 1		.	a •••	Person	6 D 6.	
1.Title of	(State) 2. Transaction Date (Month/Day/Year)	2A. Deemo	ed Date, if	3.	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	Securities F Beneficially (Owned (Following (Reported Transaction(s) (Instr. 3 and 4)	f, or Beneficia 5. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect
Reminder: Rep	ort on a separate lin	e for each cl	ass of sec	urities benef	ficially own	ned directly	or indirectly.		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: White Christopher G - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 5 (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Options	\$ 14.89	06/25/2012		А	40,000	(1)	06/25/2019	Common Stock	40,000	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
White Christopher G			Chief			
C/O AMAG PHARMACEUTICALS, INC.			Business			
100 HAYDEN AVENUE			Officer and			
LEXINGTON, MA 02421			SVP			
•••						

Signatures

Nancy R. Smith, attorney-in-fact 06/27/2012

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. 25% of
(1) this option will vest and become exercisable on June 25, 2013, the first anniversary of the grant, and thereafter the remainder will vest and become exercisable in equal 6.25% quarterly installments through June 25, 2016.

(2) Price is not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.